Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [4611]

A potential setback in the personalised medicine of cancer

A potential setback in the personalised medicine of cancer

Spatial protein profiling reveals variability within tumours

Spatial protein profiling reveals variability within tumours

AACR 2018: Dual inhibition of IDO1 and PD-L1 safe in patients with advanced solid tumours

AACR 2018: Dual inhibition of IDO1 and PD-L1 safe in patients with advanced solid tumours

AACR 2018: TLR9 agonist CMP-001 / pembrolizumab combination shows early efficacy in patients with metastatic melanoma resistant to anti-PD-1

AACR 2018: TLR9 agonist CMP-001 / pembrolizumab combination shows early efficacy in patients with metastatic...

AACR 2018: Updated data for durvalumab plus tremelimumab for NSNSCLC

AACR 2018: Updated data for durvalumab plus tremelimumab for NSNSCLC

FDA approves nivolumab plus ipilimumab combination for intermediate or poor-risk advanced renal cell carcinoma

FDA approves nivolumab plus ipilimumab combination for intermediate or poor-risk advanced renal cell carcinoma

AACR 2018: Combination therapy strengthens T cells in melanoma pre-clinical study

AACR 2018: Combination therapy strengthens T cells in melanoma pre-clinical study

AACR 2018: Strategies identified to reverse obesity’s lingering, pro-cancer effects

AACR 2018: Strategies identified to reverse obesity’s lingering, pro-cancer effects

New study discovers cancer-relevant protein shield

New study discovers cancer-relevant protein shield

AACR 2018: Tumours' drug resistance measured up to 10 times faster

AACR 2018: Tumours' drug resistance measured up to 10 times faster

More from ecancer